V
EGFA induced new blood vessel formation is essential for promotion, progression and metastasis of solid tumours 1, 2 . VEGFA by acting mainly via its VEGFR-2 present in the endothelial cells promotes angiogenesis by inducing microvascular permeability, endothelial cell proliferation, migration and tube formation 1, 2 . Accordingly, several anti-angiogenic agents are being presently used in the clinics targeting this cytokine and VEGFR-2 for the treatment of several types of solid tumours 3, 4 . However, these anti-angiogenic drugs are very expensive and it is therefore prudent to identify newer, inexpensive and effective anti-angiogenic molecules 5 . We have very recently demonstrated that Triphala (THL), a mixture of three myrobalan fruits can significantly inhibit VEGFA induced angiogenesis 6, 7 . Previous reports have indicated that in addition to gallic acid and ellagic acid, chebulagic acid (CA), benzopyran tannin is also a major constituent of THL 8, 9 . Since plasma levels and bioavailability of gallic acid and ellagic acid following oral ingestion are poor 10, 11 , therefore it is possible that other bioactive constituents of THL may be responsible for the anti-VEGFA actions of this mixture 7 . This study thus investigated the effects of CA at a concentration present in THL on VEGFA mediated regulation of proangiogenic endothelial cells functions.
Results and Discussion
Plasma concentration of CA in mice after oral feeding of THL. Since our previous report indicated significant inhibition of VEGFA mediated angiogenesis by THL and because CA present in the THL may have anti-VEGFA effects, we therefore at first investigated the plasma level of CA after gavaging mice with THL [7] [8] [9] . Our LC-MS/MS data indicated that the concentrations of CA in plasma were 4341.67 ng/ml (,5 mM) at 10 min, 2098.33 ng/ml (,2 mM) at 30 min and 1795.00 ng/ml (,1 mM) at 2 hr after oral feeding of these animals with a single nontoxic dose of 100 mg/kg of THL containing 22.2 mg/kg of CA (Figure 1 ).
Cytotoxic effects of CA on endothelial cells. Thereafter, the effects of 1, 2 and 5 mM of CA on the viability of human umbilical vein endothelial cells (HUVEC) were determined because these plasma concentrations of CA reached when mice were gavaged with a single non toxic VEGFA inhibitory dose (100 mg/kg) of THL ( Figure 1 ). Our results indicated that 1, 2 and 5 mM of CA had no effects on cell viability (Figure 2 ). Therefore 1, 2 and 5 mM of CA were selected for our in vitro experiments.
Effects of CA on endothelial cell functions. Since VEGFA induces angiogenesis by stimulating endothelial cell permeability, proliferation, migration and tube formation and 5 mM) of CA detected in mice following THL intake on these VEGFA mediated endothelial cell functions. We observed that 2 and 5 mM of CA significantly inhibited VEGFA (20 ng/ml) induced endothelial cell proliferation (Figure 3 ), migration (Figure 4a and 4b) and tube formation (Figure 5a , 5b, 5c, 5d, 5e and 5f). In addition, 2 and 5 mM of CA also significantly inhibited VEGFA mediated endothelial cell permeability in vitro ( Figure 6 ). On the contrary, no such effects were observed when these cells were treated only with CA (data not shown). In addition, we observed that 2 and 5 mM of CA could significantly inhibit VEGFA induced VEGFR-2 phosphorylation in these cells (Figure 7a and 7b) , thereby suggesting the molecular mechanism of VEGFA inhibitory actions of this natural compound. However, 1 mM of CA had no such significant effects on VEGFA mediated activation of VEGFR-2 ( Figure 7c and 7d).
Effects of CA on angiogenesis in chick chorioallantoic membrane (CAM) assay. Furthermore as our in vitro data indicated that CA could significantly inhibit the pro-angiogenic actions of VEGFA ( Figure 3 , 4, 5, 6, 7), we next examined the effects of CA (1, 2 and 5 mM) on VEGFA induced angiogenesis using CAM assay 7, 12, 13 . New blood vessel formation or angiogenesis was not detected on treatment with the vehicle (phosphate buffered saline solution) (Figure 8a and 8f). In contrast, prominent angiogenesis was seen on treatment with 250 ng of VEGFA (Figure 8b and 8f). Furthermore, although 1 mM of CA had no prominent effects, there was significant inhibition of VEGFA mediated angiogenesis after treatment with 2 and 5 mM of CA ( Figure 8c , 8d, 8e and 8f). Importantly, CA alone had no effects on angiogenesis (data not shown). These observations were made on Day 4 after treatment with CA.
In conclusion, this study demonstrates that CA by suppressing VEGFA mediated activation of VEGFR-2 inhibits the pro-angiogenic actions of this cytokine on endothelial cells. Because angiogenesis plays an important role in many pathological conditions such as malignant tumours, rheumatoid arthritis and diabetic retinopathy, therefore this natural molecule may be used as an effective antiangiogenic agent for the treatment of these diseases in future 14 .
Methods
Reagents. Triphala and more than 90% pure CA were purchased from Dabur, New Delhi, India and Natural Remedies, Bangalore, India respectively. The recombinant human VEGFA was procured from R&D systems, MN, USA. The CA and other solutions used for the experiments were free from endotoxin as determined by gelclot limulus amebocyte lysate assay (Charles River, MA, USA) 15 . All other chemicals were from Sigma, MO, USA.
Detection of plasma CA in mice. All animal experiments were undertaken following the approved protocol of Institutional Animal Care and Use Committee of the Ohio State University. 6-8 wks old, C57BL/6 male mice were at first gavaged with a single non-toxic dose (100 mg/kg) of THL 7 . Blood was then collected by cardiac puncture at different time intervals followed by separation of plasma. The level of CA in plasma was finally determined by LC-MS/MS 7 .
Endothelial cell culture. HUVEC were cultured in endothelial basal medium (EBM) supplemented with growth factors and 2% FBS (Lonza, CA, USA). All HUVEC experiments unless specified were undertaken in 24 hrs serum and growth factor starved cells 7, 16, 17 .
In vitro toxicity assay. In order to determine the cytotoxicity of CA, trypan blue dye exclusion test was done to examine the viability of the cells. 2 3 10 4 endothelial cells were at first treated with 1, 2 and 5 mM of CA. 200 ml of 0.4% w/v trypan blue (SigmaAldrich, MO, USA) was then added to these cells followed by counting of the stained cells 12 .
Proliferation assay. 5 3 10 3 HUVEC were either untreated or treated with VEGFA (20 ng/ml) or VEGFA (20 ng/ml) 1 CA (1, 2 and 5 mM) for 24 hr. Prestoblue TM Cell
Viability reagent (Invitrogen, NY, USA) was used as per instructions of the manufacturer to detect proliferation of these cells 7, 18 .
Wound healing assay. After wounding the HUVEC monolayers with a 200 ml pipette, the effects of CA on VEGFA mediated migration were determined in both untreated cells or cells treated with VEGFA (20 ng/ml) or VEGFA (20 ng/ml) 1 CA (1, 2 and 5 mM). The closure of wound was determined at 16 hr by the distance covered by these cells in relation to the initial distance. The results were expressed as percentage of wound healed 7, 17 .
Endothelial cell tube formation assay. In vitro angiogenesis assay kit (Millipore, CA, USA) was used as per the manufacturers instructions to determine the effect of CA on HUVEC tube formation. In brief, HUVEC treated either with phosphate buffered saline or VEGFA (20 ng/ml) or VEGFA (20 ng/ml) 1 CA (1, 2 and 5 mM) were seeded on extra cellular matrix to form capillary tubes. The tubular structures were manually quantified by counting the numbers of connected cells in randomly selected fields and the total tube numbers in the control group was designated as 100% 7, 19 .
In vitro endothelial cell permeability assay. This assay was undertaken as per the instructions of the manufacturer using in vitro vascular permeability assay kit (Millipore, CA, USA). 2 3 10 5 HUVEC were seeded onto collagen coated inserts in 24 well plates. The respective inserts containing HUVEC were then pre-treated with 1, 2 and 5 mM of CA for 24 hr. Thereafter, FITC-Dextran containing phenol free medium containing 20 ng/ml of VEGFA was added and the fluorescence was measured at 485 nm/535 nm 7, 17 .
Western Blot. Rabbit monoclonal antibody against phospho VEGFR-2 purchased from Cell Signaling, MA, USA was used to detect VEGFR-2 phosphorylation. The protein loads were normalized using antibody for b actin (Sigma, MO, USA) and the antibody reactive bands were quantified by densitometry 7, 20, 21 .
Chick chorioallantoic membrane (CAM) assay. Semi-quantitative CAM assay was utilized to determine the effects of CA on VEGFA stimulated new blood vessel formation or angiogenesis. At first, windows were created on the shells of Leghorn chicken eggs (Ohio State University Farms, Columbus, USA) at day 3 of fertilization to expose the CAM. 1-mm 3 sterilized gelatin sponge (Pfizer, MI, USA) soaked either phosphate buffered saline (PBS) (control), or VEGFA (250 ng) or VEGFA (250 ng) 1 CA (1, 2 and 5 mM) was then aseptically inserted onto the CAM on day 8. Formation of new blood vessel formation was scored on day 12 as negative (0); change in vessel architecture (0.5); partial spoke of a wheel (1/3 of circumference exhibited directional angiogenesis) (1); spoke of a wheel (2); strong and fully spoke of a wheel Statistical analysis. ANOVA and unpaired Student's t test or Dunn's multiple comparison tests were used to analyze the differences among the groups. P , 0.05 was considered to be significant 16, 20 .
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